BERKELEY, CA (UroToday.com) - Recent changes within the health care environment have focused on patient safety and quality of care, with a priority on the monitoring and tracking of relevant metrics.
BERKELEY, CA (UroToday.com) - With Washington’s frequent and fierce budget battles and recent implementation of the Affordable Care Act, policymakers and physicians alike have been forced to take a critical look at health care costs.
SAN DIEGO, CA USA (UroToday.com) - Dr. Ashish Kamat, of the M.D. Anderson Cancer Center, reported on a randomized, double-blind, placebo-controlled trial in radical cystectomy patients evaluating the potential benefit of alvimopan (alv).
BERKELEY, CA (UroToday.com) - Age is a risk factor for the occurrence of bladder cancer and bladder cancer is a disease of the elderly.
BERKELEY, CA (UroToday.com) - In this article, we set out to determine the impact of the learning curve at a newly established robotic cystectomy program.
BERKELEY, CA (UroToday.com) - Muscle-invasive bladder cancer is a potentially lethal disease that affects a large number of patients in the United States each year.
BERKELEY, CA (UroToday.com) - Approximately 70% of patients with newly diagnosed bladder cancer (BC) present with stage Ta, CIS or T1.(1)
BERKELEY, CA (UroToday.com) - This article aims to review and summarize the literature and data in regards to robot-assisted radical cystectomy (RARC).
BERKELEY, CA (UroToday.com) -
Partial cystectomy in patients with invasive bladder cancer: is it a good option?
To investigate the long-term cumulative incidence of chronic urinary retention (CUR) after radical cystectomy (RC) and orthotopic neobladder (ONB) in women and the possible risk factors.
We retrospectively analyzed a prospectively evaluated cohort of women for whom RC and ONB were performed.
STOCKHOLM, SWEDEN (UroToday.com) - Neoadjuvant chemotherapy (NAC) offers a survival benefit to patients with muscle-invasive bladder cancer (MIBC).
Fistula formation is a rare and poorly described complication following radical cystectomy with urinary diversion. We sought to identify patients who experienced any type of fistulous complication and analyze the risk factors for formation as well as management outcomes.
View Slide Presentation
Level I evidence suggests that administration of systemic chemotherapy prior to radical cystectomy affords an overall survival benefit in patients with muscle invasive bladder cancer.
SAN FRANCISCO, CA USA (UroToday.com) - Presented by Matthew D. Galsky, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA
Bladder cancer (BCa) is a disease of the elderly and as the population is aging, BCa will become an even bigger public health challenge in the future. Nowadays the correct management of BCa in the elderly remains controversial.
Patients after radical cystectomy (RC) frequently complain about bowel disorders (BDs). Reports addressing related long-term complications are sparse. This cross-sectional study assessed changes in bowel habits (BH) after RC.
Locally advanced (T3b, T4 and N1-N3) and metastatic urothelial bladder cancer (BCa) is a lethal disease with poor survival outcomes. Combination chemotherapy remains the treatment of choice in patients with metastatic disease and an important part of treatment in addition to radical cystectomy (RC) in patients with locally advanced tumour.
BACKGROUND:Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard of care for high-risk non-muscle-invasive and muscle-invasive bladder cancer (BCa).
BERKELEY, CA (UroToday.com) - Radical cystectomy (RC), followed by urinary diversion or reconstruction, is a standard treatment for patients with muscle-invasive bladder cancer.
BERKELEY, CA (UroToday.com) - Bladder cancer remains a significant and common cancer in the United States, with the estimated number of new diagnoses being 54 610 in men and 17 960 in women in 2013.
Login to update email address, newsletter preferences and use bookmarks.